- Home
- OTLK vs SCWO Comparison
OTLK vs SCWO Comparison
Compare OTLK & SCWO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- SCWO
- Stock Information
- Founded
- OTLK 2010
- SCWO 2021
- Country
- OTLK United States
- SCWO United States
- Employees
- OTLK N/A
- SCWO N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- SCWO Environmental Services
- Sector
- OTLK Health Care
- SCWO Utilities
- Exchange
- OTLK Nasdaq
- SCWO Nasdaq
- Market Cap
- OTLK 48.3M
- SCWO 39.9M
- IPO Year
- OTLK 2016
- SCWO N/A
- Fundamental
- Price
- OTLK $1.53
- SCWO $0.32
- Analyst Decision
- OTLK Strong Buy
- SCWO
- Analyst Count
- OTLK 5
- SCWO 0
- Target Price
- OTLK $10.20
- SCWO N/A
- AVG Volume (30 Days)
- OTLK 274.9K
- SCWO 166.7K
- Earning Date
- OTLK 05-19-2025
- SCWO 05-15-2025
- Dividend Yield
- OTLK N/A
- SCWO N/A
- EPS Growth
- OTLK N/A
- SCWO N/A
- EPS
- OTLK N/A
- SCWO N/A
- Revenue
- OTLK N/A
- SCWO $445,445.00
- Revenue This Year
- OTLK N/A
- SCWO $5,945.19
- Revenue Next Year
- OTLK $288.46
- SCWO $106.82
- P/E Ratio
- OTLK N/A
- SCWO N/A
- Revenue Growth
- OTLK N/A
- SCWO N/A
- 52 Week Low
- OTLK $0.87
- SCWO $0.25
- 52 Week High
- OTLK $9.25
- SCWO $1.99
- Technical
- Relative Strength Index (RSI)
- OTLK 55.94
- SCWO 57.19
- Support Level
- OTLK $1.35
- SCWO $0.26
- Resistance Level
- OTLK $1.62
- SCWO $0.29
- Average True Range (ATR)
- OTLK 0.10
- SCWO 0.03
- MACD
- OTLK -0.00
- SCWO 0.01
- Stochastic Oscillator
- OTLK 54.55
- SCWO 85.80
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About SCWO 374Water Inc.
374Water Inc offers a technology that transforms wet wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, and forever chemicals (e.g., PFAS) into recoverable resources by focusing on waste as a valuable resource for water, energy, and minerals. The company's business activities include manufacturing processes and waste recycling and treatment processes, which currently involve the use, treatment, storage, transfer, handling and/or disposal of hazardous materials, chemicals and wastes.